Intellectual Property India Publishes Patent Application for 'Compounds And Methods For Modulating Alpha-Synuclein Expression' Filed by Ionis Pharmaceuticals, Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202547088045 A) filed by Ionis Pharmaceuticals, Inc., Carlsbad, U.S.A., on Sept. 16, for 'compounds and methods for modulating alpha-synuclein expression.'

Inventor(s) include Zhao, Hien, Thuy; Freier, Susan, M.; Wan, W., Brad; Thomas, Antony; Migawa, Michael, T; Seth, Punit, P.; and Fitzsimmons, Bethany.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "Provided herein are compounds, phannaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in certain instances reducing the amount of alpha-synuclein protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of a synucleinopathy. Such synucleinopathies include Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multiple system atrophy (MSA), neuronopathic Gaucher's disease, and Alzheimer's disease."

The patent application was internationally filed on Feb. 16, 2024, under International application No.PCT/US2024/016097.

Disclaimer: Curated by HT Syndication.